Guggenheim Cuts Genmab A/S (NASDAQ:GMAB) Price Target to $40.00

Genmab A/S (NASDAQ:GMAB) had its price objective dropped by equities researchers at Guggenheim from $45.00 to $40.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 37.13% from the company’s current price.

GMAB has been the subject of a number of other research reports. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. HC Wainwright boosted their price objective on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Truist Financial reissued a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Finally, Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.70.

Genmab A/S Price Performance

Shares of GMAB traded down $0.12 during trading hours on Monday, hitting $29.17. 1,146,283 shares of the company were exchanged, compared to its average volume of 1,834,491. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43. The company has a market cap of $18.74 billion, a price-to-earnings ratio of 18.82, a P/E/G ratio of 0.96 and a beta of 0.90. The firm’s fifty day moving average is $32.15 and its 200 day moving average is $30.03.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. On average, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of Genmab A/S during the 4th quarter valued at about $697,000. Dorsey Wright & Associates purchased a new stake in Genmab A/S in the fourth quarter worth approximately $1,381,000. Corient Private Wealth LLC grew its position in Genmab A/S by 10.9% during the fourth quarter. Corient Private Wealth LLC now owns 17,469 shares of the company’s stock valued at $535,000 after acquiring an additional 1,724 shares during the last quarter. Braeburn Wealth Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth approximately $1,084,000. Finally, Vident Advisory LLC raised its stake in shares of Genmab A/S by 11.4% during the fourth quarter. Vident Advisory LLC now owns 39,707 shares of the company’s stock worth $1,223,000 after acquiring an additional 4,060 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.